Zobrazeno 1 - 10
of 20
pro vyhledávání: '"D. S. Boss"'
Autor:
William Copalu, A. Mazur, Jantien Wanders, M Keesen, R. Morrison, D. S. Boss, Jos H. Beijnen, J P O'Brien, Jan H.M. Schellens, Hilary Glen, Thomas J. Evans, B Tait
Publikováno v:
British Journal of Cancer
Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to expl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::829756bf3d74dbdd2f3e8f13873b85b4
http://europepmc.org/articles/PMC3349182
http://europepmc.org/articles/PMC3349182
Autor:
D. S. Boss, T.R. Jeffry Evans, Jantien Wanders, Hilary Glen, Jan H.M. Schellens, Daphne de Jong, Jos H. Beijnen
Publikováno v:
Tumori Journal. 97:109-114
Background Elevated β-HCG serum levels are usually an indication of pregnancy or pregnancy-related disorders, but β-HCG can also be elevated in testis and germ cell tumors. HCG expression by osteosarcoma is a rare phenomenon, with a few documented
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47935589e58009947f2231f17803011
https://doi.org/10.1177/030089161109700119
https://doi.org/10.1177/030089161109700119
Publikováno v:
Current Clinical Pharmacology. 5:192-195
The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical model
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51987e756f503daa456718b8d5c8e70b
https://doi.org/10.2174/157488410791498798
https://doi.org/10.2174/157488410791498798
Publikováno v:
The Oncologist. 14:780-793
The aurora kinase family of serine/threonine kinases comprises three members, designated auroras A, B, and C. Auroras A and B are essential components of the mitotic pathway, ensuring proper chromosome assembly, formation of the mitotic spindle, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c6c5e23c90b0952575c05ca0991f7ed
https://doi.org/10.1634/theoncologist.2009-0019
https://doi.org/10.1634/theoncologist.2009-0019
Autor:
Peijun Wu, Andrew Tutt, James Carmichael, Marja Mergui-Roelvink, Peter C.C. Fong, Alan Lau, Helen Swaisland, Alan Ashworth, Peter S. Mortimer, Timothy A. Yap, Stan B. Kaye, D. S. Boss, Jan H.M. Schellens, Johann S. de Bono, Mark J. O'Connor
Publikováno v:
New England Journal of Medicine. 361:123-134
The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a30a36dbd71050ea918e6fce1045a5
https://doi.org/10.1056/nejmoa0900212
https://doi.org/10.1056/nejmoa0900212
Publikováno v:
The Oncologist. 13:25-38
Learning Objectives After completing this course, the reader will be able to: Describe the advantages of combined PET/CT over single PET and single CT imaging.Mention the applications of combined PET/CT in the evaluation of novel anticancer drugs.Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::058fd37f81ed54bcc801582203178a90
https://doi.org/10.1634/theoncologist.2007-0097
https://doi.org/10.1634/theoncologist.2007-0097
Autor:
Robert Millham, Pasi A. Jänne, S. Gail Eckhardt, Jeffrey A. Engelman, Ian Taylor, Steven G. Wong, D. Ross Camidge, Jan H.M. Schellens, Carolyn D. Britten, D. S. Boss, Stephen P. Letrent, Edward B. Garon, Jane Q. Liang, Feng Guo
Purpose: PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. This first-in-human study investigated the safety, tolerability, pharmacokinetics, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4eddd1d0570a68bb7bd3932cc043fb5
https://europepmc.org/articles/PMC3048920/
https://europepmc.org/articles/PMC3048920/
Autor:
Stan B. Kaye, Alan Ashworth, D. S. Boss, Christina Messiou, John F. Stone, Peter C.C. Fong, James Carmichael, Jacques De Greve, Johann S. de Bono, Roger A'Hern, Andrew Tutt, Jan H.M. Schellens, Craig P. Carden, Jan Lubinski, Timothy A. Yap, Marja Mergui-Roelvink, Susan Shanley, Charlie Gourley
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc817aad57a3be44547bce41ce9ccba
https://biblio.vub.ac.be/vubir/polyadpribose-polymerase-inhibition-frequent-durable-responses-in-brca-carrier-ovarian-cancer-correlating-with-platinumfree-interval(b84b0caf-4919-4aa8-9a60-732f11b5c85b).html
https://biblio.vub.ac.be/vubir/polyadpribose-polymerase-inhibition-frequent-durable-responses-in-brca-carrier-ovarian-cancer-correlating-with-platinumfree-interval(b84b0caf-4919-4aa8-9a60-732f11b5c85b).html
Autor:
Sarah Danson, D. S. Boss, Hilary Calvert, Jan H.M. Schellens, Mark R. Middleton, Helen Swaisland, Malcolm R Ranson, Richard D. Carvajal, Rachel Midgley, Lucian R. Chirieac, Gary K. Schwartz, D D Amakye, Geoffrey I. Shapiro, Clive Morris, Ruth Plummer
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 21(4)
Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57ffb15a41ad68f33522af1fe17e974b
https://pubmed.ncbi.nlm.nih.gov/19825886
https://pubmed.ncbi.nlm.nih.gov/19825886
Autor:
Dick Pluim, D. S. Boss, Hilde Rosing, Nadja E. van Egmond-Schoemaker, Jos H. Beijnen, Jan H.M. Schellens, W. S. Siegel-Lakhai, Wim W. ten Bokkel Huinink
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13)
Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this interaction, the following phase I trial was designed to determine the safety and maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0d9f69eace1d670fa0c09537799202b
https://pubmed.ncbi.nlm.nih.gov/19531625
https://pubmed.ncbi.nlm.nih.gov/19531625